Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -128.66% is in line with its 5-year average of -133.94%, around the middle of its 5-year range (-223.94%–-19.00%).
39.97% above its 12-month average of -214.31%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -14.97%.
RETURN ON ASSETS (ROA)
-128.66%
RETURN ON ASSETS (ROA) AVG TTM
-214.31%
RETURN ON ASSETS (ROA) AVG 3Y
-145.75%
RETURN ON ASSETS (ROA) AVG 5Y
-133.94%
RETURN ON ASSETS (ROA) AVG 10Y
-110.56%
RETURN ON ASSETS (ROA) AVG 15Y
-93.29%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+39.97%
CURRENT VS 3Y AVG
+11.73%
CURRENT VS 5Y AVG
+3.94%
CURRENT VS 10Y AVG
-16.37%
CURRENT VS 15Y AVG
-37.91%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-29.12%
median of 605 covered companies
CURRENT VS SECTOR MEDIAN
-341.83%
vs the sector median at left
Indaptus Therapeutics, Inc.
Market Cap
$272.91M
Return on Assets (ROA)
-128.66%
TTM Avg
-214.31%
3Y Avg
-145.75%
5Y Avg
-133.94%
Market Cap
$272.17M
Return on Assets (ROA)
-48.44%
TTM Avg
-42.51%
3Y Avg
-39.18%
5Y Avg
-34.60%
Market Cap
$275.95M
Return on Assets (ROA)
-18.18%
TTM Avg
-10.00%
3Y Avg
-29.10%
5Y Avg
-54.94%
Market Cap
$279.56M
Return on Assets (ROA)
-35.03%
TTM Avg
-13.04%
3Y Avg
-43.14%
5Y Avg
-55.84%
Market Cap
$281.16M
Return on Assets (ROA)
-26.24%
TTM Avg
-12.09%
3Y Avg
-27.60%
5Y Avg
-33.24%
Market Cap
$258.34M
Return on Assets (ROA)
-37.07%
TTM Avg
-27.27%
3Y Avg
-64.53%
5Y Avg
-52.03%
Market Cap
$259.30M
Return on Assets (ROA)
-35.96%
TTM Avg
-58.88%
3Y Avg
-82.10%
5Y Avg
-113.46%
Market Cap
$258.48M
Return on Assets (ROA)
-134.38%
TTM Avg
-47.50%
3Y Avg
-42.91%
5Y Avg
-40.55%
Market Cap
$286.94M
Return on Assets (ROA)
-48.34%
TTM Avg
-34.05%
3Y Avg
-4876.46%
5Y Avg
-3907.18%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | $272.91M | -128.66% | -214.31% | -145.75% | -133.94% |
| Fate Therapeutics, Inc. (FATE)vs › | $272.17M | -48.44% | -42.51% | -39.18% | -34.60% |
| Aurora Cannabis Inc. (ACB)vs › | $275.95M | -18.18% | -10.00% | -29.10% | -54.94% |
| Abeona Therapeutics Inc. (ABEO)vs › | $279.56M | -35.03% | -13.04% | -43.14% | -55.84% |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.16M | -26.24% | -12.09% | -27.60% | -33.24% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $258.34M | -37.07% | -27.27% | -64.53% | -52.03% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.30M | -35.96% | -58.88% | -82.10% | -113.46% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $258.48M | -134.38% | -47.50% | -42.91% | -40.55% |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $286.94M | -48.34% | -34.05% | -4876.46% | -3907.18% |
| AC Immune S.A. (ACIU)vs › | $258.00M | -29.15% | -33.84% | -33.85% | -31.54% |
ROA
-128.7%
ROE
-135.6%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -223.94% |
| 2024-12-31 | -204.69% |
| 2023-12-31 | -103.35% |
| 2022-12-31 | -51.04% |
| 2021-12-31 | -19.00% |
| 2020-12-31 | -201.61% |
| 2019-12-31 | -223.68% |
| 2018-12-31 | -70.79% |
| 2017-12-31 | -44.79% |
| 2016-12-31 | -54.05% |
| 2015-12-31 | -19.25% |
| 2014-12-31 | -45.57% |
| 2013-12-31 | -37.24% |
| 2012-12-31 | -66.71% |
| 2011-12-31 | -83.69% |
| 2010-12-31 | -43.25% |
| 2009-12-31 | -119.72% |
| 2008-12-31 | -248.26% |
